BGNE

BeiGene, Ltd. (BGNE)

Last Price$226.70.0%
Market Cap$1,846.9M
LTM Return on Equity (ROE)
(25.3%)
5Y avg
(39.3%)
Biotechnology industry median
(52.8%)
Stock quality & Intrinsic value
5/10
11.4% undervalued

BeiGene, Ltd. Return on Equity (ROE)

Annual
Quarterly
LTM
Industry median
Company stand-alone
BGNE
Healthcare
Crunching data... Almost there!
Dec'13Dec'14Dec'15Dec'16Dec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23
Return on Equity (ROE)
20.4%
286.2%
(443.2%)
0.0%
(27.3%)
(55.3%)
(69.6%)
(66.0%)
(28.0%)
(37.7%)
(22.3%)
BGNE
Key metrics and insights to make informed decisions.
View full analysis
Overvalued or undervalued?
Check the intrinsic value for BGNE and see if it's the right time to invest.
Dive in

BeiGene, Ltd. (BGNE) Return on Equity (ROE) comparison analysis

Crunching data... Almost there!

BGNE key stats

USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
Crunching data... Almost there!

Discover more Stock Ideas

FAQ

1) What is BeiGene, Ltd.'s Return on Equity (ROE)?

As of today, Microsoft Corp's last 12-month Return on Equity (ROE) is (25.3%), based on the financial report for Sep 30, 2024 (Q3 2024). The average annual Return on Equity (ROE) for BeiGene, Ltd. have been (32.5%) over the past three years, and (41.2%) over the past five years.

2) Is BeiGene, Ltd.'s Return on Equity (ROE) Good?

As of today, BeiGene, Ltd.'s Return on Equity (ROE) is (25.3%), which is higher than industry median of (52.8%). It indicates that BeiGene, Ltd.'s Return on Equity (ROE) is Good.

3) How does BeiGene, Ltd.'s Return on Equity (ROE) compare to its peers?

As of today, BeiGene, Ltd.'s Return on Equity (ROE) is (25.3%), which is lower than peer median of (0.8%). The list of peers includes NVO, UTHR, REGN, INCY, RPRX, BNTX, VRTX, ARGX, SMMT, ALNY.